News & Updates
Filter by Specialty:
ALA-PDT on par with minocycline for moderate-to-severe rosacea
Patients with moderate-to-severe rosacea may benefit from treatment with 5-aminolevulinic acid photodynamic therapy (ALA-PDT), which has shown its efficacy and noninferiority to minocycline in a recent study.
ALA-PDT on par with minocycline for moderate-to-severe rosacea
08 Oct 2023ICI-related adverse events tied to longer survival in metastatic NSCLC
Immune-related adverse events (irAEs) are more likely to develop in metastatic nonsmall cell lung cancer (NSCLC) patients with certain prognostic characteristics, suggests a study. Interestingly, those who develop irAEs benefit from a much longer overall survival (OS) and time to next treatment when mitigating immortal time bias.
ICI-related adverse events tied to longer survival in metastatic NSCLC
08 Oct 2023Canakinumab improves survival in advanced NSCLC
Treatment with canakinumab appears beneficial to patients with advanced nonsmall cell lung cancer (NSCLC) with low T-cell infiltration (ie, low total count or immune desert phenotype), results of predefined exploratory biomarker analyses from the CANOPY-1 have shown.
Canakinumab improves survival in advanced NSCLC
07 Oct 2023Liraglutide vs semaglutide: Which is a better GLP-1 RA for diabetic veterans?
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) liraglutide and semaglutide are both effective at lowering haemoglobin A1c (A1c) among veterans with type 2 diabetes mellitus (T2DM), reports a recent study, which provides insights into key considerations for this population.